Association between Wnt signaling pathway gene polymorphisms and bone response to hormone therapy in postmenopausal Korean women

Menopause

Volumn 18, Issue 7, 2011, Pages 808-813

  Kim, Hoon ^a   Choe, Seung Ah ^b   Ku, Seung Yup ^b,c   Kim, Seok Hyun ^b,c   Kim, Jung Gu ^b,c  

^a Division of Infectious Diseases   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Bone mineral density; Hormone therapy; Nonresponder.; Polymorphism; Wnt signaling pathway gene

Indexed keywords

APC PROTEIN; AXIN; ESTROGEN; FRIZZLED PROTEIN; FRIZZLED RECEPTOR 6; GESTAGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; OSTEOPROTEGERIN; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ADULT; ALLELE; ARTICLE; BONE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; ESTROGEN THERAPY; ETHNIC GROUP; FEMALE; FEMUR NECK; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HORMONAL THERAPY; HUMAN; KOREAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; BONE DENSITY; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LDL-RECEPTOR RELATED PROTEINS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; POLYMORPHISM, GENETIC; PROGESTINS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 79959730638     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e318208f9b2     Document Type: Article

References (23)

1. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000;17:1-45.
2. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115:3318-3325. (Pubitemid 43121814)
3. Jouanny P, Guillemin F, Kuntz C, Jeandel C, Pourel J. Environmental and genetic factors affecting bone mass. Similarity of bone density among members of healthy families. Arthritis Rheum 1995;38:61-67.
4. Ralston SH. Genetics of osteoporosis. Ann N Y Acad Sci 2010:1192; 181-189.
5. Rosen CJ, Rackoff PJ. Emerging anabolic treatments for osteoporosis. Rheum Dis Clin North Am 2001;27:215-233, viii. (Pubitemid 32240605)
6. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 2003;423:349-355. (Pubitemid 40852710)
7. Rawadi G, Roman-Roman S. Wnt signalling pathway: a new target for the treatment of osteoporosis. Expert Opin Ther Targets 2005;9: 1063-1077. (Pubitemid 41488840)
8. Johnson ML, Harnish K, Nusse R, Van Hul W. LRP5 and Wnt signaling: a union made for bone. J Bone Miner Res 2004;19:1749-1757. (Pubitemid 41103424)
9. Ezura Y, Nakajima T, Urano T, et al. Association of a single-nucleotide variation (A1330V) in the low-density lipoprotein receptorYrelated protein 5 gene (LRP5) with bone mineral density in adult Japanese women. Bone 2007;40:997-1005. (Pubitemid 46386523)
10. Sims AM, Shephard N, Carter K, et al. Genetic analyses in a sample of individuals with high or low BMD shows association with multiple Wnt pathway genes. J Bone Miner Res 2008;23:499-506. (Pubitemid 351501890)
11. Lee DY, Kim H, Ku SY, Kim SH, Choi YM, Kim JG. Association between polymorphisms in Wnt signaling pathway genes and bone mineral density in postmenopausal Korean women. Menopause 2010;17: 1064-1070.
12. Zhang ZL, Qin YJ, He JW, et al. Association of polymorphisms in lowdensity lipoprotein receptorYrelated protein 5 gene with bone mineral density in postmenopausal Chinese women. Acta Pharmacol Sin 2005; 26:1111-1116.
13. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG. Association between the A1330V polymorphism of the low-density lipoprotein receptorYrelated protein 5 gene and bone mineral density: a meta-analysis. Rheumatol Int 2009;29:539-544.
14. Komulainen M, Kroger H, Tuppurainen MT, et al. Prevention of femoral and lumbar bone loss with hormone replacement therapy and vitamin D3 in early postmenopausal women: a population-based 5-year randomized trial. J Clin Endocrinol Metab 1999;84:546-552. (Pubitemid 29075682)
15. Komulainen M, Kroger H, Tuppurainen MT, Heikkinen AM, Honkanen R, Saarikoski S. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial. Osteoporos Int 2000;11:211-218. (Pubitemid 30216172)
16. Hassager C, Jensen SB, Christiansen C. Non-responders to hormone replacement therapy for the prevention of postmenopausal bone loss: do they exist? Osteoporos Int 1994;4:36-41. (Pubitemid 24034444)
17. Kim JG, Choi YM, Moon SY, Lee JY. Association of the calcitonin gene (CA) polymorphism with bone mass and bone responsiveness to hormone therapy in postmenopausal Korean women. Menopause 2003;10: 544-549.
18. Deng HW, Li J, Li JL, et al. Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes. Hum Genet 1998;103:576-585. (Pubitemid 28548480)
19. Silvestri S, Thomsen AB, Gozzini A, Bagger Y, Christiansen C, Brandi ML. Estrogen receptor and A polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy? Menopause 2006;13:451-461.
20. Yim CH, Choi JT, Choi HA, et al. Association of estrogen receptor gene microsatellite polymorphism with annual changes in bone mineral density in Korean women with hormone replacement therapy. J Bone Miner Metab 2005;23:395-400. (Pubitemid 41223803)
21. Brodowska A, Starczewski A, Brodowski J, Szydlowska I, Nawrocka- Rutkowska J. The bone mass density in postmenopausal women using hormonal replacement therapy in relation to polymorphism in vitamin D receptor and estrogen receptor genes. Gynecol Endocrinol 2009;25: 315-323.
22. Kim JG, Kim H, Jee BC, Suh CS, Choi YM, Moon SY. Non-assocation between polymorphisms of frizzled receptor genes and bone mineral density in postmenopausal women. J Korean Med Sci 2009;24:443-447.
23. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-549. (Pubitemid 36159890)